Macrogenics Inc.

MGNX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001125345

C

middle fifth of 369 graded peers in healthcare

rank 181 of 369; percentile 48.9; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise



Scoreboard	
Profitability	B/C percentile 40.6
Solvency	C percentile 51.2
Growth and financing	C percentile 50.8
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $256.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 9, 2026 249 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$2.29 2026-11-12; market equity $146.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries. "MacroGenics®, the MacroGenics logo, DART®, TRIDENT® and the phrases Breakthrough Biologics, Life-Changing Medicines® and Developing Breakthrough Biologics, Life-Changing Medicines® are our trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.6						
Gross profitability	58.2%	32.3%		18.1	365	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	2.5%	(6.6%)	85.0	800	2025-12-31
Gross margin stability, five years	1.2 pts	2.8 pts	18.7	242	2025-12-31
Solvency, sleeve percentile 51.2					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(12.89)	(0.35)	66.6	744	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Current ratio	5.10x	2.95x	35.8	826	2025-12-31
Growth and financing, sleeve percentile 50.8					
Revenue growth, three-year compound	(0.5%)	10.1%	72.3	412	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(2.9%)	2.2%	58.3	694	2025-12-31
Net share issuance, one year	0.7%	2.5%	21.7	627	2026-03-05

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
176	Kymera Therapeutics, Inc. (KYMR)	47.6	C	dilution
177	ClearPoint Neuro, Inc. (CLPT)	47.8	C	
178	Scynexis Inc. (SCYX)	48.1	C	fortress balance sheet
179	UroGen Pharma Ltd. (URGN)	48.4	C	
180	Amneal Pharmaceuticals, Inc. (AMRX)	48.6	C	
181	Macrogenics Inc. (MGNX)	48.9	C	
182	Biodesix Inc. (BDSX)	49.2	C	dilution
183	Evolus, Inc. (EOLS)	49.5	C	
184	Savara Inc. (SVRA)	49.7	C	short runway, fortress balance sheet
185	Neogen Corp. (NEOG)	50.0	C	late filer
186	Neuroone Medical Technologies Corp. (NMTC)	50.3	C	short runway, fortress balance sheet

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	132.5%	(1.9%)	93
Distance from 52-week high	(52.9%)	(30.8%)	28
EBIT to enterprise value	not computable	(1.9%)	
Free cash flow yield	(56.7%)	(1.0%)	13

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.17	0.28	36
Sales to price	1.02	0.29	82
Composite equity issuance, five years	12.8%	20.5%	43
Relative strength against the sector, log excess return	0.68	(0.19)	93

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$49.0M
Operating cash flow, four quarters	-$39.9M
Months of runway	14.8
Days since last periodic filing	1 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$1.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$149.5M	2025-12-31	2026-03-09	10-K	26-000017
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$0	2025-12-31	2026-03-09	10-K	26-000017
3	assets	us-gaap:Assets	$256.8M	2025-12-31	2026-03-09	10-K	26-000017
4	net income	us-gaap:NetIncomeLoss	-$74.6M	2025-12-31	2026-03-09	10-K	26-000017
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$81.0M	2025-12-31	2026-03-09	10-K	26-000017
6	assets	us-gaap:Assets	$261.7M	2024-12-31	2026-03-09	10-K	26-000017
7	revenue	us-gaap:Revenues	$150.0M	2024-12-31	2026-03-09	10-K	26-000017
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$847,000	2024-12-31	2026-03-09	10-K	26-000017
9	revenue	us-gaap:Revenues	$58.7M	2023-12-31	2026-03-09	10-K	26-000017
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$619,000	2023-12-31	2026-03-09	10-K	26-000017
11	revenue	us-gaap:Revenues	$151.9M	2022-12-31	2025-03-20	10-K	25-000042
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$3.4M	2022-12-31	2025-03-20	10-K	25-000042
13	revenue	us-gaap:Revenues	$77.4M	2021-12-31	2024-03-07	10-K	24-000060
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.7M	2021-12-31	2024-03-07	10-K	24-000060
15	current assets	us-gaap:AssetsCurrent	$219.9M	2025-12-31	2026-03-09	10-K	26-000017
16	current liabilities	us-gaap:LiabilitiesCurrent	$43.1M	2025-12-31	2026-03-09	10-K	26-000017
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2025-12-31	2026-03-09	10-K	26-000017
18	operating income	us-gaap:OperatingIncomeLoss	-$72.8M	2025-12-31	2026-03-09	10-K	26-000017
19	book equity	us-gaap:StockholdersEquity	$55.6M	2025-12-31	2026-03-09	10-K	26-000017
20	liabilities	us-gaap:Liabilities	$201.3M	2025-12-31	2026-03-09	10-K	26-000017
21	operating income	us-gaap:OperatingIncomeLoss	-$110.6M	2024-12-31	2026-03-09	10-K	26-000017
22	interest expense	us-gaap:InterestExpense	$1.1M	2024-12-31	2025-03-20	10-K	25-000042
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.9M	2025-12-31	2026-03-09	10-K	26-000017
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$68.4M	2024-12-31	2026-03-09	10-K	26-000017
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.7M	2024-12-31	2026-03-09	10-K	26-000017
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$78.2M	2023-12-31	2026-03-09	10-K	26-000017

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.8M	2023-12-31	2026-03-09	10-K	26-000017
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$87.0M	2022-12-31	2025-03-20	10-K	25-000042
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.6M	2022-12-31	2025-03-20	10-K	25-000042
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$7.2M	2025-12-31	2026-03-09	10-K	26-000017
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$75.3M	2025-12-31	2026-03-09	10-K	26-000017
32	income tax	us-gaap:IncomeTaxExpenseBenefit	-$672,000	2025-12-31	2026-03-09	10-K	26-000017
33	current assets	us-gaap:AssetsCurrent	$217.5M	2024-12-31	2026-03-09	10-K	26-000017
34	current liabilities	us-gaap:LiabilitiesCurrent	$55.5M	2024-12-31	2026-03-09	10-K	26-000017
35	assets	us-gaap:Assets	$298.4M	2023-12-31	2025-03-20	10-K	25-000042
36	assets	us-gaap:Assets	$280.5M	2022-12-31	2024-03-07	10-K	24-000060
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,555,837	2026-03-05	2026-03-09	10-K	26-000017
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,090,323	2025-03-14	2025-03-20	10-K	25-000042

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.